JP2021506898A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506898A5 JP2021506898A5 JP2020534265A JP2020534265A JP2021506898A5 JP 2021506898 A5 JP2021506898 A5 JP 2021506898A5 JP 2020534265 A JP2020534265 A JP 2020534265A JP 2020534265 A JP2020534265 A JP 2020534265A JP 2021506898 A5 JP2021506898 A5 JP 2021506898A5
- Authority
- JP
- Japan
- Prior art keywords
- form according
- solution
- crystalline form
- crystal
- values
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 34
- 239000013078 crystal Substances 0.000 claims description 27
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000001228 spectrum Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609512P | 2017-12-22 | 2017-12-22 | |
| US62/609,512 | 2017-12-22 | ||
| PCT/US2018/066769 WO2019126482A1 (en) | 2017-12-22 | 2018-12-20 | Crystalline forms of nicotinamide riboside chloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021506898A JP2021506898A (ja) | 2021-02-22 |
| JP2021506898A5 true JP2021506898A5 (https=) | 2021-11-18 |
Family
ID=66993830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020534265A Pending JP2021506898A (ja) | 2017-12-22 | 2018-12-20 | ニコチンアミドリボシドクロリドの結晶形態 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11414407B2 (https=) |
| EP (1) | EP3727400A4 (https=) |
| JP (1) | JP2021506898A (https=) |
| CN (1) | CN112020363A (https=) |
| CA (1) | CA3086535A1 (https=) |
| WO (1) | WO2019126482A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11129843B2 (en) | 2017-04-24 | 2021-09-28 | Elysium Health, Inc. | Treating and preventing kidney damage |
| CN112020363A (zh) | 2017-12-22 | 2020-12-01 | 益力舒健康公司 | 烟酰胺核苷氯化物的结晶形式 |
| BR112022000963A2 (pt) | 2019-07-19 | 2022-04-05 | Biosynth Ag | Método de fabricação de sais de nicotinamida ribofuranosídeo, sais de nicotinamida ribofuranosídeo como tal e usos dos mesmos |
| CN111454311B (zh) * | 2020-04-03 | 2021-10-19 | 深圳市迪克曼科技开发有限公司 | 烟酰胺核糖的有机酸盐及其组合物与制备方法 |
| CN111808156A (zh) * | 2020-07-15 | 2020-10-23 | 许昌远志生物科技有限公司 | 一种β-烟酰胺核糖氯化物的晶型1A、晶型1B及其制备方法 |
| CN121793959A (zh) | 2023-06-14 | 2026-04-03 | 可劳迈戴斯有限公司 | 静脉内配制品中的烟酰胺核苷及其衍生物与使用方法 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1190080A (en) | 1966-08-08 | 1970-04-29 | Kyowa Hakko Kogyo Company Ltd | Process for producing Nicotinamide Adenine Dinucleotide |
| US3728111A (en) | 1971-09-21 | 1973-04-17 | Asea Ab | Method of manufacturing billets from powder |
| DK0981534T3 (da) | 1997-02-06 | 2006-09-04 | Inspire Pharmaceuticals Inc | Dinukleotider og deres anvendelser |
| GB9712370D0 (en) | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
| WO2002048165A2 (en) | 2000-12-15 | 2002-06-20 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
| US7179791B2 (en) | 2001-01-11 | 2007-02-20 | Duke University | Inhibiting GS-FDH to modulate NO bioactivity |
| JP3748536B2 (ja) | 2001-02-09 | 2006-02-22 | 三共株式会社 | ピリミジンヌクレオシド誘導体の結晶 |
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US20050020587A1 (en) | 2003-07-25 | 2005-01-27 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US8114626B2 (en) | 2004-02-10 | 2012-02-14 | Trustees Of Dartmouth College | Yeast strain and method for using the same to produce nicotinamide riboside |
| JP2007521835A (ja) | 2004-02-10 | 2007-08-09 | トラスティーズ・オブ・ダートマウス・カレッジ | ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法 |
| JP2008501343A (ja) | 2004-06-04 | 2008-01-24 | ワシントン・ユニバーシティ | 神経障害を治療するための方法および組成物 |
| NZ561613A (en) | 2005-02-18 | 2010-12-24 | Astrazeneca Ab | Antibacterial piperidine derivatives |
| US20060229265A1 (en) | 2005-03-30 | 2006-10-12 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| US20070149466A1 (en) | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| EP3369738B1 (en) | 2005-11-18 | 2020-05-20 | Cornell Research Foundation, Inc. | Method for making nicotinoyl ribosides and nicotinamide beta-riboside |
| EP1957109A2 (en) | 2005-12-02 | 2008-08-20 | Sirtris Pharmaceuticals, Inc. | Modulators of cdc2-like kinases (clks) and methods of use thereof |
| WO2007136744A1 (en) | 2006-05-19 | 2007-11-29 | The Johns Hopkins University | Crystal structure of a substrate complex of nampt/pbef/visfatin |
| EP2129660A2 (en) | 2006-12-19 | 2009-12-09 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| EP2124985A4 (en) | 2007-01-26 | 2011-06-08 | Univ Washington | METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS |
| CA2725481A1 (en) | 2008-06-18 | 2009-12-23 | Pfizer Limited | Nicotinamide derivatives |
| WO2010002586A2 (en) | 2008-06-30 | 2010-01-07 | Elc Management Llc | Topical compositions comprising isonicotinamide |
| SG194404A1 (en) | 2008-12-23 | 2013-11-29 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| US8815894B2 (en) | 2009-05-12 | 2014-08-26 | Bristol-Myers Squibb Company | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
| US20120164670A1 (en) | 2009-06-23 | 2012-06-28 | President And Fellows Of Harvard College | Methods and kits for measuring enzyme activity |
| WO2011011721A2 (en) | 2009-07-24 | 2011-01-27 | Amazentis Sa | Compounds, compositions and methods for protecting brain health in neurodegenerative disorders |
| US8507251B2 (en) | 2009-09-28 | 2013-08-13 | Robert J. Greenstein | Medium and method for culturing Mycobacterium avium subspecies paratuberculosis |
| US9603862B2 (en) | 2009-12-14 | 2017-03-28 | Cornell University | Activation and activators of SIRT5 |
| US20130165398A1 (en) | 2010-03-29 | 2013-06-27 | Paul Hochegger | Concentration-enhancing drink |
| JP5663576B2 (ja) | 2010-07-06 | 2015-02-04 | 秀則 上西 | 神経突起伸長剤 |
| WO2012114204A2 (en) | 2011-02-15 | 2012-08-30 | Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto | Methods of treating mitochondrial dysfunction |
| US20120107888A1 (en) | 2011-02-17 | 2012-05-03 | Qteros, Inc. | Modulation of fermentation products through vitamin supplementation |
| US20120328526A1 (en) | 2011-06-27 | 2012-12-27 | University Of Maryland, Baltimore | Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof |
| EP3345901A3 (en) | 2011-06-29 | 2018-09-12 | President and Fellows of Harvard College | Small molecules as antiaging agents |
| CN104780782A (zh) | 2012-07-09 | 2015-07-15 | 诺格罗有限责任公司 | 使用膳食补充剂预防酒精反应 |
| US20140256760A1 (en) | 2012-07-09 | 2014-09-11 | Noglo Llc | Reduction or prevention of alcohol reaction with dietary supplements |
| EP2872128B1 (en) | 2012-07-16 | 2020-02-19 | Cornell University | Nicotinamide riboside to treat hearing loss |
| AU2013329312A1 (en) | 2012-10-09 | 2015-05-28 | Massachusetts Institute Of Technology | Treatment of age-related and mitochondrial diseases by inhibition of HIF-1 alpha function |
| WO2014111906A1 (en) | 2013-01-21 | 2014-07-24 | Ecole Polytechnique Federale De Lausanne (Epfl) | Bioluminescence imaging of small biomolecules |
| CN105228627B (zh) | 2013-03-15 | 2018-07-13 | 纽斯尔特科学公司 | 亮氨酸和烟酸降低脂质水平 |
| GB201313465D0 (en) | 2013-07-29 | 2013-09-11 | Queens University Of The Belfast | Methods of preparing nicotinamide riboside and derivatives thereof |
| EP3060311B1 (en) | 2013-10-24 | 2019-05-22 | The Procter and Gamble Company | Skin lightening cosmetic compositions and methods |
| WO2015064988A1 (ko) | 2013-10-29 | 2015-05-07 | 한림대학교 산학협력단 | 니코틴아마이드 라이보사이드를 유효성분으로 포함하는 패혈증 치료 또는 예방용 약제학적 조성물 |
| KR20220098049A (ko) | 2013-10-30 | 2022-07-08 | 크로마덱스 아이엔씨. | 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물 |
| CN105992521A (zh) | 2013-11-12 | 2016-10-05 | 奥索努特拉有限责任公司 | 基于特咖宁的补充剂及其使用方法 |
| WO2015099842A1 (en) | 2013-12-23 | 2015-07-02 | Abbott Laboratories | Hot beverage fortifier |
| EP3116851B1 (en) | 2014-03-13 | 2023-07-26 | Salk Institute for Biological Studies | Analogs of fexaramine and methods of making and using |
| US20150297508A1 (en) | 2014-04-21 | 2015-10-22 | William Andriette | Topical Formulation to Enhance Genital Sensation and Function |
| JP2017518306A (ja) * | 2014-06-02 | 2017-07-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | 結晶性β−Ｄ−ニコチンアミドリボシドの製造および使用 |
| CN107073027A (zh) | 2014-07-17 | 2017-08-18 | 斯克利普斯研究院 | 增强癌症疗法的方法和组合物 |
| US10323058B2 (en) * | 2014-07-24 | 2019-06-18 | W. R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| EP3268379B1 (en) | 2015-03-09 | 2023-11-01 | W.R. Grace & CO. - CONN. | Crystalline form of nicotinamide riboside |
| JP7061077B2 (ja) | 2016-04-14 | 2022-04-27 | クロマデックス，インコーポレイテッド | ニコチンアミドリボシド、ニコチン酸リボシド、ニコチンアミドモノヌクレオチド、およびニコチノイル化合物誘導体の、乳児用粉ミルクへの使用 |
| WO2017218580A1 (en) * | 2016-06-14 | 2017-12-21 | Rejuvenation Therapeutics Corporation | Synthetic methods for the preparation of nicotinamide riboside and related compounds |
| EP3538099B1 (en) | 2016-11-11 | 2026-04-22 | The Queen's University of Belfast | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
| CN112020363A (zh) | 2017-12-22 | 2020-12-01 | 益力舒健康公司 | 烟酰胺核苷氯化物的结晶形式 |
| BR112022000963A2 (pt) | 2019-07-19 | 2022-04-05 | Biosynth Ag | Método de fabricação de sais de nicotinamida ribofuranosídeo, sais de nicotinamida ribofuranosídeo como tal e usos dos mesmos |
| CN111808156A (zh) | 2020-07-15 | 2020-10-23 | 许昌远志生物科技有限公司 | 一种β-烟酰胺核糖氯化物的晶型1A、晶型1B及其制备方法 |
-
2018
- 2018-12-20 CN CN201880090063.7A patent/CN112020363A/zh active Pending
- 2018-12-20 EP EP18892817.0A patent/EP3727400A4/en not_active Withdrawn
- 2018-12-20 WO PCT/US2018/066769 patent/WO2019126482A1/en not_active Ceased
- 2018-12-20 US US16/955,412 patent/US11414407B2/en active Active
- 2018-12-20 CA CA3086535A patent/CA3086535A1/en active Pending
- 2018-12-20 JP JP2020534265A patent/JP2021506898A/ja active Pending
-
2022
- 2022-08-12 US US17/887,060 patent/US12043616B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021506898A5 (https=) | ||
| CN1243541C (zh) | 2－(α－羟基戊基)苯甲酸盐及其制法和用途 | |
| JP2021504310A5 (https=) | ||
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| CN103201262A (zh) | 自分泌运动因子抑制剂及其用途 | |
| JP2015520151A5 (https=) | ||
| TW201035048A (en) | New salt and crystalline forms | |
| CN108349906B (zh) | 依托咪酯衍生物及其中间体、制备方法和用途 | |
| US11155537B2 (en) | Crystal of benzofuran derivative free base and preparation method | |
| JP2013519665A (ja) | メシル酸イマチニブのα形の製造方法 | |
| WO2020020230A1 (zh) | 一类双阳离子化合物及其制备方法和用途 | |
| JP2013511475A5 (https=) | ||
| JP6310923B2 (ja) | ジヒドロピリミジン誘導体の結晶形 | |
| CN106632267A (zh) | 一种伏立康唑的合成方法 | |
| CN102131803A (zh) | (1r，2s，3r)-1-(2-(异噁唑-3-基)-1h-咪唑-4-基)丁烷-1，2，3，4-四醇的固体形式及其使用方法 | |
| JP2004504390A (ja) | （ｒ）−ｎ−［５−メチル−８−（４−メチルピペラジン−１−イル）−１，２，３，４−テトラヒドロ−２−ナフチル］−４−モルホリノベンズアミドの新規な形態 | |
| CN103923168A (zh) | 一种阿加曲班一水合物的制备方法 | |
| WO2008051637A2 (en) | Pyridazinone compounds | |
| JP3353784B2 (ja) | 公知のブラジキニン拮抗剤のガラス体 | |
| JP2021513963A (ja) | 異常増殖性疾患を治療するための薬剤および方法 | |
| WO2019037161A1 (zh) | 一种合成氯法齐明关键中间体n-(4-氯苯基)-1，2-苯二胺的方法 | |
| WO2017020869A1 (zh) | 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺的晶型b及其制备方法和应用 | |
| CN1261364A (zh) | 具血管生成抑制性的噻二唑基哒嗪衍生物 | |
| CN104326983A (zh) | 一种塞来昔布的精制方法 | |
| CN105440045B (zh) | 一种纳布啡酸式盐的精制工艺 |